Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have earned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.
Analysts have set a 12 month consensus price target of $15.50 for the company and are anticipating that the company will post ($0.77) EPS for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 19th.
In related news, COO Augustine Lawlor purchased 1,057,769 shares of the stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $6.09 per share, for a total transaction of $6,441,813.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 58.40% of the company’s stock.
Leap Therapeutics (LPTX) traded up $0.18 on Tuesday, hitting $6.24. The stock had a trading volume of 97,952 shares, compared to its average volume of 68,874. Leap Therapeutics has a 1-year low of $4.90 and a 1-year high of $9.44.
Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). analysts predict that Leap Therapeutics will post -3.63 EPS for the current year.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.